Progress in HIV vaccine development. PMID: 28281871
A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PMID: 24068931
A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses. PMID: 31672916
mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice. PMID: 35294883
Structure-guided envelope trimer design in HIV-1 vaccine development: a narrative review. PMID: 34806305
Structural Survey of Broadly Neutralizing Antibodies Targeting the HIV-1 Env Trimer Delineates Epitope Categories and Characteristics of Recognition. PMID: 30471922
Complete epitopes for vaccine design derived from a crystal structure of the broadly neutralizing antibodies PGT128 and 8ANC195 in complex with an HIV-1 Env trimer. PMID: 26457433
Broadly Neutralizing Antibody 8ANC195 Recognizes Closed and Open States of HIV-1 Env. PMID: 26359989
Conformation-Dependent Interactions Between HIV-1 Envelope Glycoproteins and Broadly Neutralizing Antibodies. PMID: 29905080
Analysis of two cooperating antibodies unveils immune pressure imposed on HIV Env to elicit a V3-glycan supersite broadly neutralizing antibody lineage. PMID: 36225920
HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies. PMID: 26869204
The HIV glycan shield as a target for broadly neutralizing antibodies. PMID: 26411545
A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic β-Hairpin Structure. PMID: 28423342
Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic. PMID: 34123998
Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. PMID: 23426631
Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at Its Apex. PMID: 28978711
A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch. PMID: 33084569
A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex. PMID: 32669335
Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design. PMID: 27168247
[Requirements for the Induction of Broadly Neutralizing Antibodies against HIV-1 by Vaccination]. PMID: 29271959
Nanoparticle Vaccines for Inducing HIV-1 Neutralizing Antibodies. PMID: 31362378
Neutralization tiers of HIV-1. PMID: 29266013
Mapping Neutralizing Antibody Epitope Specificities to an HIV Env Trimer in Immunized and in Infected Rhesus Macaques. PMID: 32905766
VSV-Displayed HIV-1 Envelope Identifies Broadly Neutralizing Antibodies Class-Switched to IgG and IgA. PMID: 32315598
Highly mutated antibodies capable of neutralizing N276 glycan-deficient HIV after a single immunization with an Env trimer. PMID: 35263576
HIV Coinfection Provides Insights for the Design of Vaccine Cocktails to Elicit Broadly Neutralizing Antibodies. PMID: 35758668
Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability. PMID: 31732167
CD4 occupancy triggers sequential pre-fusion conformational states of the HIV-1 envelope trimer with relevance for broadly neutralizing antibody activity. PMID: 30650070
Neutralizing antibodies induced in immunized macaques recognize the CD4-binding site on an occluded-open HIV-1 envelope trimer. PMID: 35136084
HIV-1 Envelope Glycosylation and the Signal Peptide. PMID: 33669676
Rapid elicitation of broadly neutralizing antibodies to HIV by immunization in cows. PMID: 28726771
Insights into the trimeric HIV-1 envelope glycoprotein structure. PMID: 25600289
Stabilizing HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies. PMID: 30208933
Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses. PMID: 34668778
Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. PMID: 26689967
Structural principles controlling HIV envelope glycosylation. PMID: 28363124
Stabilized HIV-1 envelope glycoprotein trimers for vaccine use. PMID: 28422788
Immunization with HIV-1 trimeric SOSIP.664 BG505 or founder virus C (FVCEnv) covalently complexed to two-domain CD4S60C elicits cross-clade neutralizing antibodies in New Zealand white rabbits. PMID: 36262212
The HIV-1 envelope glycoprotein structure: nailing down a moving target. PMID: 28133813
Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting. PMID: 30995238
Conformations of Human Immunodeficiency Virus Envelope Glycoproteins in Detergents and Styrene-Maleic Acid Lipid Particles. PMID: 37255444
Elicitation of potent serum neutralizing antibody responses in rabbits by immunization with an HIV-1 clade C trimeric Env derived from an Indian elite neutralizer. PMID: 33826683
Efficiently cleaved HIV-1 envelopes: can they be important for vaccine immunogen development? PMID: 33103053
Native-like Env trimers as a platform for HIV-1 vaccine design. PMID: 28133806
Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens? PMID: 32272076
Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity. PMID: 28275193
An efficiently cleaved HIV-1 clade C Env selectively binds to neutralizing antibodies. PMID: 25822521
Feline immunodeficiency virus (FIV) neutralization: a review. PMID: 22069520
HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure. PMID: 29768174
Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies. PMID: 22933274
Binding of inferred germline precursors of broadly neutralizing HIV-1 antibodies to native-like envelope trimers. PMID: 26433050
Antibody responses to envelope glycoproteins in HIV-1 infection. PMID: 25988889
Challenges for structure-based HIV vaccine design. PMID: 20048708
A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene. PMID: 25589637
Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model. PMID: 28978475
HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function. PMID: 34566999
Human immunoglobulin repertoire analysis guides design of vaccine priming immunogens targeting HIV V2-apex broadly neutralizing antibody precursors. PMID: 36179689
Antibody elicited by HIV-1 immunogen vaccination in macaques displaces Env fusion peptide and destroys a neutralizing epitope. PMID: 34697307
HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadth. PMID: 30477581
Conformational Plasticity in the HIV-1 Fusion Peptide Facilitates Recognition by Broadly Neutralizing Antibodies. PMID: 31194940
Stabilization of the V2 loop improves the presentation of V2 loop-associated broadly neutralizing antibody epitopes on HIV-1 envelope trimers. PMID: 30728245
Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop. PMID: 26763999
Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. PMID: 31126879
Live rubella vectors can express native HIV envelope glycoproteins targeted by broadly neutralizing antibodies and prime the immune response to an envelope protein boost. PMID: 30037665
Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env. PMID: 34818054
Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization. PMID: 31348886
Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. PMID: 24884783
Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies. PMID: 34731616
SOSIP Trimer-Specific Antibodies Isolated from a Simian-Human Immunodeficiency Virus-Infected Monkey with versus without a Pre-blocking Step with gp41. PMID: 34730398
Enhancing HIV-1 Neutralization by Increasing the Local Concentration of Membrane-Proximal External Region-Directed Broadly Neutralizing Antibodies. PMID: 36541800
A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention. PMID: 34328065
Functional and Highly Cross-Linkable HIV-1 Envelope Glycoproteins Enriched in a Pretriggered Conformation. PMID: 35343783
An HIV-1 Broadly Neutralizing Antibody from a Clade C-Infected Pediatric Elite Neutralizer Potently Neutralizes the Contemporaneous and Autologous Evolving Viruses. PMID: 30429339
Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies. PMID: 25253346
Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice. PMID: 26091035
Polyfunctional Tier 2-Neutralizing Antibodies Cloned following HIV-1 Env Macaque Immunization Mirror Native Antibodies in a Human Donor. PMID: 33472907
Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. PMID: 28298421
Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. PMID: 28878010
Functional development of a V3/glycan-specific broadly neutralizing antibody isolated from a case of HIV superinfection. PMID: 34263727
Structural Constraints at the Trimer Apex Stabilize the HIV-1 Envelope in a Closed, Antibody-Protected Conformation. PMID: 30538178
Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies., PMID:39235529
CoPoP liposomes displaying stabilized clade C HIV-1 Env elicit tier 2 multiclade neutralization in rabbits., PMID:38605096
Potency and durability of T and B cell immune responses after homologous and heterologous vector delivery of a trimer-stabilized, membrane-displayed HIV-1 clade ConC Env protein., PMID:38045703
Vaccination with immune complexes modulates the elicitation of functional antibodies against HIV-1., PMID:37854587
Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1-uninfected adult participants in the US., PMID:37679276
Recognition determinants of improved HIV-1 neutralization by a heavy chain matured pediatric antibody., PMID:37649696
Development of a synthetic nanoparticle vaccine presenting the HIV-1 envelope glycoprotein., PMID:35882111
CD4+ T Cells Are Dispensable for Induction of Broad Heterologous HIV Neutralizing Antibodies in Rhesus Macaques., PMID:34745131
Cyanovirin-N Binds Viral Envelope Proteins at the Low-Affinity Carbohydrate Binding Site without Direct Virus Neutralization Ability., PMID:34199200
Development of a RPLC-UV method for monitoring uncleaved HIV-1 envelope glycoprotein., PMID:33954330
Exploration of a Sequential Gp140-Gp145 Immunization Regimen with Heterologous Envs to Induce a Protective Cross-Reactive HIV Neutralizing Antibody Response In Non-human Primates., PMID:33723807
DNA adjuvant Amiloride conjunct long immunization interval promote higher antibody responses to HIV-1 gp41 and gp140 immunogens., PMID:33041100
Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor., PMID:32817216
Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development., PMID:32582155
A Systematic Approach to HIV-1 Vaccine Immunogen Selection., PMID:32056466
Trimeric HIV-1 gp140 fused with APRIL, BAFF, and CD40L on the mucosal gp140-specific antibody responses in mice., PMID:32014267
Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses., PMID:31921191
The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1., PMID:31867001
Antigenicity and immunogenicity of HIV-1 gp140 with different combinations of glycan mutation and V1/V2 region or V3 crown deletion., PMID:31564450
Associating HIV-1 envelope glycoprotein structures with states on the virus observed by smFRET., PMID:30971821
IL-33 enhances the kinetics and quality of the antibody response to a DNA and protein-based HIV-1 Env vaccine., PMID:30926296
A sequestered fusion peptide in the structure of an HIV-1 transmitted founder envelope trimer., PMID:30787293
Developability Assessment of Physicochemical Properties and Stability Profiles of HIV-1 BG505 SOSIP.664 and BG505 SOSIP.v4.1-GT1.1 gp140 Envelope Glycoprotein Trimers as Candidate Vaccine Antigens., PMID:30776383
Characterization of native-like HIV-1 gp140 glycoprotein expressed in insect cells., PMID:30737044
The adjuvant AlhydroGel elicits higher antibody titres than AddaVax when combined with HIV-1 subtype C gp140 from CAP256., PMID:30557314
An HIV-1 Broadly Neutralizing Antibody from a Clade C-Infected Pediatric Elite Neutralizer Potently Neutralizes the Contemporaneous and Autologous Evolving Viruses., PMID:30429339
SOSIP Changes Affect Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Conformation and CD4 Engagement., PMID:30021898
Multivalent Antigen Presentation Enhances the Immunogenicity of a Synthetic Three-Component HIV-1 V3 Glycopeptide Vaccine., PMID:29806004
Envelope proteins of two HIV-1 clades induced different epitope-specific antibody response., PMID:29429810
Hidden Lineage Complexity of Glycan-Dependent HIV-1 Broadly Neutralizing Antibodies Uncovered by Digital Panning and Native-Like gp140 Trimer., PMID:28883821
High-Throughput Protein Engineering Improves the Antigenicity and Stability of Soluble HIV-1 Envelope Glycoprotein SOSIP Trimers., PMID:28878072
Selection of nanobodies with broad neutralizing potential against primary HIV-1 strains using soluble subtype C gp140 envelope trimers., PMID:28827559
Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide., PMID:28298421
Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers., PMID:28246356
Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial., PMID:28235027
Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers., PMID:28202756
Trimeric gp120-specific bovine monoclonal antibodies require cysteine and aromatic residues in CDRH3 for high affinity binding to HIV Env., PMID:27996375
Human Antibodies that Recognize Novel Immunodominant Quaternary Epitopes on the HIV-1 Env Protein., PMID:27411063
Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles., PMID:27349934
HIV-1 Vaccine-elicited Antibodies Reverted to Their Inferred Naive Germline Reveal Associations between Binding Affinity and in vivo Activation., PMID:26879974
Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop., PMID:26763999
Complete epitopes for vaccine design derived from a crystal structure of the broadly neutralizing antibodies PGT128 and 8ANC195 in complex with an HIV-1 Env trimer., PMID:26457433
Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers., PMID:26311893
HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers., PMID:26089353
A New Approach to Produce HIV-1 Envelope Trimers: BOTH CLEAVAGE AND PROPER GLYCOSYLATION ARE ESSENTIAL TO GENERATE AUTHENTIC TRIMERS., PMID:26088135
Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers., PMID:26051934
Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1 Envelope Glycoprotein Trimers and Soluble gp140., PMID:26018173
Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer., PMID:25807248
Directed evolution of a yeast-displayed HIV-1 SOSIP gp140 spike protein toward improved expression and affinity for conformational antibodies., PMID:25688555
DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers., PMID:25631080
For research use only. Not for human or drug use.
